<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>24269406</identifier>
<setSpec>1989-7286</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Asensio-Sánchez, V M</dc:author>
<dc:author>Trujillo-Guzmán, L</dc:author>
<dc:author>Ramoa-Osorio, R</dc:author>
<dc:description xml:lang="en">CASE REPORT A woman, treated with immunomodulatory and immunosuppressive drugs for multiple sclerosis, developed macular oedema 4 months after oral fingolimod administration. The patient was previously seen by an ophthalmologist, with a normal anterior segment and funduscopic examination. Four months after the treatment she referred to decreased visual acuity in both eyes. The funduscopic and OCT examination now revealed cystoid macular oedema (CME). DISCUSSION Attention to visual changes and periodic funduscopic examinations are an important part of monitoring while using fingolimod. In our patient early recognition and discontinuation of fingolimod did not result in resolution of the CME.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:subject>Multiple sclerosis</dc:subject>
<dc:subject>Fingolimod</dc:subject>
<dc:subject>Macular oedema</dc:subject>
<dc:subject>Visual acuity</dc:subject>
<dc:subject>Esclerosis múltiple</dc:subject>
<dc:subject>Irreversible</dc:subject>
<dc:subject>Agudeza visual</dc:subject>
<dc:subject>Edema macular</dc:subject>
<dc:date>2014 Mar </dc:date>
<dc:title xml:lang="es">Edema macular quístico por fingolimod en esclerosis múltiple.</dc:title>
<dc:title xml:lang="en">[Cystoid macular oedema after fingolimod treatment in multiple sclerosis].</dc:title>
<dc:publisher>Archivos de la Sociedad Espanola de Oftalmologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
